Coastal Infusion Administers Ruxience™
| HCPCS Code | Q5119 |
|---|---|
| Manufacturer | Pfizer |
| First Approved | 07/23/2019 |
Coastal Infusion can administer your Ruxience prescription at any of our south Florida locations.
Ruxience (rituximab) is used in the treatment of various blood cancers and inflammatory conditions.
The active substance in Ruxience, rituximab, is a monoclonal antibody, designed to attach to a protein, called CD20, present on B lymphocytes. When rituximab attaches to CD20, it causes the death of B lymphocytes, which helps in lymphoma and chronic lymphocytic leukemia (CLL) (where B-lymphocytes have become cancerous) and in rheumatoid arthritis (where B lymphocytes are involved in joint inflammation). In GPA and MPA, destroying the B-lymphocytes lowers the production of antibodies that attack blood vessels and cause inflammation.
What It Treats
- Non-Hodgkin’s lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis
- Pemphigus vulgaris
Prescribed By
- Oncologists
- Rheumatologists
- Hematologists
- Dermatologists
How it’s Administered
Ruxience is administered by intravenous infusion. Ruxience infusions take between 4 and 6 hours.
Frequency
The frequency of Ruxience infusions varies, depending on the condition being treated.
Related Drugs
Additional Resources
The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies